Report : North America Hemodialysis and Peritoneal Dialysis Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Hemodialysis and Peritoneal Dialysis), Product (Devices, Consumables, and Services), and End User (Hospital-Based and Home-Based)

At 6.0% CAGR, the North America Hemodialysis and Peritoneal Dialysis market is speculated to be worth US$ 45,277.56 million by 2028, says Business Market Insights

According to Business Market Insights’ research, the North America hemodialysis and peritoneal dialysis market was valued at US$ 31,852.39 million in 2022 and is expected to reach US$ 45,277.56 million by 2028, registering an annual growth rate of 6.0% from 2021 to 2028. Rising prevalence of kidney diseases and increasing cases of diabetes are the critical factors attributed to the market expansion.

Diabetes occurs when blood glucose, also called blood sugar, is too high. High blood glucose can cause health problems over time. The main types of diabetes are type 1, type 2, and gestational. According to International Diabetes According to the CDC, in 2020, more than 34 million Americans had diabetes, which is nearly 11% of the US population. According to the American Diabetes Association [ADA], approximately 1.5 million new cases of diabetes are registered every year. According to the World Health Organization, there are about 60 million people with diabetes in Europe and about 10.3% of men and 9.6% of women aged 25 years and over suffer from diabetes. Further, diabetes is more common among older people.

With diabetes, the small blood vessels in the body are injured. When the blood vessels in the kidneys are injured, the kidneys cannot clean the blood properly. The body will retain more water and salt than it should, resulting in weight gain and ankle swelling. Also, waste materials will build up in the blood. Diabetes may also cause damage to nerves in the body, which can cause difficulty in emptying the bladder. The pressure resulting from a full bladder can back up and injure the kidneys. According to a study, about 30% of patients with Type 1 (juvenile-onset) diabetes and 10–40% of those with Type 2 (adult-onset) diabetes will eventually suffer from kidney failure. Therefore, an increase in the prevalence of diabetes also increases the chances of dialysis for a patient's survival, thereby fueling the market growth.

On the contrary, various risks and complications associated with dialysis hurdles the growth of North America hemodialysis and peritoneal dialysis market.

Based on type, the North America hemodialysis and peritoneal dialysis market is bifurcated into hemodialysis and peritoneal dialysis. The former held 85.6% market share in 2022, amassing US$ 27,279.66 million. It is projected to garner US$ 39,508.37 million by 2028 to expand at 6.4% CAGR during 2022–2028.     

Based on product, the hemodialysis and peritoneal dialysis market is segmented into devices, consumables, and services. With 56.1% share of the domain, the services segment dominated the market in 2020. It accrued US$ 17,869.11 million in 2022 and is estimated to generate US$ 25,337.87 million by 2028 to grow at a CAGR of 6.0% over the forecast period.

Based on end user, the hemodialysis and peritoneal dialysis market is segmented into hospital-based and home-based. The hospital-based segment held a larger share in 2022 with a market share of 78.9%. Further it accrued US$ 25,205.16 million in 2022 and is expected to reach at US$ 35,267.24 million at a decent CAGR of 5.8% during the forecast period.

Our regional analysis states that US captured 84.8% market share in 2022. It was assessed at US$ 27,001.28 million in 2022 and is likely to hit US$ 38,082.96 million by 2028, exhibiting a CAGR of 5.9% during the forecast period.  

Key players dominating the North America hemodialysis and peritoneal dialysis market are Asahi Kasei Medical Co., Ltd.; B. Braun Melsungen AG; Baxter International Inc.; DaVita Inc.; Dialife SA; Evoqua Water Technologies LLC. (Mar Cor Purification); Fresenius Medical Care AG & Co KGaA; Nipro Medical Corporation; and Rockwell Medical, Inc., among others.

The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance:

  • DaVita Inc. announced the expansion of its collaboration with Fresenius Medical Care's North American FMS division to provide NxStage home hemodialysis machines and related technologies to patients in the United States. In particular, the agreement supports companies' efforts to allow more people with renal failure to choose home dialysis as an option.
  • B. Braun Melsungen AG acquires a specialist in the preparation of dialysis concentrates, Intermedt Medizin & Technik GmbH. The acquisition has helped B. Braun Melsungen AG to complete the extensive product portfolio of its B. Braun Avitum division as a systems provider for extracorporeal blood treatment (dialysis).

Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email Id:

Download Free PDF Brochure